FIELD: biotechnology.
SUBSTANCE: there are presented monoclonal antibodies or their antigen-binding fragments directed against ILT2, as well as pharmaceutical compositions containing them. Also disclosed are nucleic acid molecules coding said antibodies or fragments thereof, expression vectors and host cells containing said nucleic acids, a method of producing antibodies. In addition, there are presented methods of treating cancer, involving administering the antibodies of the present invention.
EFFECT: invention provides increased activity of immune cells directed against tumour cells, and can find further application in cancer therapy.
23 cl, 87 dwg, 3 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS CONTAINING ANTI-SEAMS 1 AND ANTI-PD ANTIBODIES FOR CANCER THERAPY | 2014 |
|
RU2697522C1 |
| ANTI-HLA-G ANTIBODIES AND THEIR USE | 2019 |
|
RU2797724C2 |
| ANTIBODIES AGAINST HUMAN VSIG4 AND APPLICATION THEREOF | 2019 |
|
RU2776638C1 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| ANTI-αvβ8 ANTIBODIES AND COMPOSITIONS AND THEIR USE | 2019 |
|
RU2812478C2 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| CHIMERIC ANTIBODY/T-CELL RECEPTOR STRUCTURES AND THEIR APPLICATIONS | 2016 |
|
RU2767209C2 |
| CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND THEIR USE | 2018 |
|
RU2780020C2 |
| ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
| NEW CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS CONTAINING TNFR2 DOMAINS | 2019 |
|
RU2808254C2 |
